Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,176.75

15.48 (1.33%)

, MYL

Mylan

$36.53

-0.33 (-0.90%)

07:47
12/01/17
12/01
07:47
12/01/17
07:47

Amazon price target raised to $1,525 from $1,430 at Wells Fargo

Wells Fargo analyst Ken Sena raised his price target for Amazon.com (AMZN) to $1,525 to reflect increased outer-year estimates for Web Services as well as a higher sum-of-the-parts valuation. The stock closed yesterday up $15.48 to $1,176.75. The analyst highlights the "very successful" five-day Amazon Wed Services conference in Las Vegas, "record-breaking" early holiday sales data, and another healthcare industry development with CNBC reporting the company is in talks with generic manufacturers Mylan (MYL) and Novartis (NVS). Sena sees an increasing likelihood that Amazon "ultimately becomes a disruptor" in healthcare, with generics representing a potential point of entry. The Wells Fargo Healthcare team sees generics as a "simple entry point" in pharma as it involves many players with ready supply and a price competitive market, Sena tells investors in a research note. The analyst keeps an Outperform rating on Amazon.

AMZN

Amazon.com

$1,176.75

15.48 (1.33%)

MYL

Mylan

$36.53

-0.33 (-0.90%)

NVS

Novartis

$85.80

0.65 (0.76%)

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 18

    Jan

  • 18

    Mar

  • 17

    May

AMZN Amazon.com
$1,176.75

15.48 (1.33%)

12/01/17
BMOC
12/01/17
UPGRADE
Target $142
BMOC
Outperform
VMware upgraded to Outperform at BMO Capital on faster computing growth
As reported earlier, BMO Capital analyst Keith Bachman upgraded VMware (VMW) to Outperform from Market Perform and raised his price target to $142 from $136. Bachman says the company is benefiting from improved on-premise spending trends, increasing his projections for the overall FY19 computing spend to grow 3% versus prior forecast of 1-2% decline. The analyst also says that management is being conservative in suggesting that the partnership with AWS (AMZN) would not generate returns for the next 2 years after attending AWS re:Invent this week.
11/30/17
RBCM
11/30/17
NO CHANGE
RBCM
Amazon.com's AWS offers scale and traction across verticals, says RBC Capital
RBC Capital analyst Mark Mahaney reflects on Amazon.com's AWS event that was much wider attended that in recent years. Mahaney says the company's presentation "highlighted the public cloud's significant appeal in organizations that span nearly every industry vertical". The analyst notes that Amazon's technical prowess make it a clear industry leader as evidenced by AWS expanding its market segment share by 5 points to 44%.
11/30/17
MKMP
11/30/17
NO CHANGE
Target $1350
MKMP
Buy
Amazon.com price target raised to $1,350 from $1,275 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Amazon to $1,350 and kept his Buy rating, keeping his view of the company as "the best long-term growth story available to large-cap investors today". Sanderson notes that the trend of AWS margin expansion will continue over the coming quarters. The analyst also believes that management can and should continue to reinvest aggressively, adding that "we are still not holding our breath on profits" despite the "richer" business mix.
12/01/17
WELS
12/01/17
NO CHANGE
WELS
Wells not seeing Amazon talks as good news for Mylan, others
CNBC last night reported that Amazon.com (AMZN) is in exploratory talks with Mylan (MYL) and Novartis' Sandoz (NVS) regarding a potential entry into the pharmacy space. While the market might consider this good news for Mylan and other generics as a sign of potential preferred supplier agreements, Wells Fargo analyst David Maris says he's more cautious. Amazon entering the pharmacy market could be a negative headwind for retail generics and potentially branded over-the-counter products, Maris argues. He believes Amazon would source at competitive prices and that "increased price transparency may cause traditional retailers to push harder for price concessions."
MYL Mylan
$36.53

-0.33 (-0.90%)

10/31/17
WELS
10/31/17
NO CHANGE
WELS
Market Perform
Wells sees 'substantial headline risk' for Mylan from probe
Today's expanded collusion probe into generic price fixing will be a "significant overhang" for several generic drug manufacturers, Wells Fargo analyst David Maris tells investors in an intraday research note. For Mylan (MYL), the specific addition of Rajiv Malik, the company's second-highest-ranking executive, creates "substantial headline risk," and may prove to be a distraction to someone many consider one of the key operational managers, Maris adds. He believes the expanding probe will cause many investors to steer clear of an already struggling sector. The analyst has Market Perform ratings on both Mylan and Teva (TEVA). Mylan in midday trading is down 7% to $35.59.
11/07/17
SUSQ
11/07/17
NO CHANGE
Target $47
SUSQ
Positive
Mylan positioned to deliver near-term growth, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes Mylan is favorably positioned relative to peers to deliver near-term growth despite headwinds while advancing a long-term strategy. He said the shares warrant a premium to traditional peers who face tougher growth challenges. Finkelstein reiterated his Positive rating and raised his price target to $47 from $43 on Mylan.
11/07/17
RBCM
11/07/17
NO CHANGE
Target $37
RBCM
Sector Perform
Mylan price target raised to $37 from $32 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Mylan to $37 and kept his Sector Perform rating. The analyst says that in spite of two consecutive challenging quarters that showed the company is not immune to broader sector challenges, Mylan's relative positioning remains favorable to peers, adding that generic Copaxone performance is helpful in the near term.
NVS Novartis
$85.80

0.65 (0.76%)

11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/20/17
JPMS
11/20/17
DOWNGRADE
Target $82
JPMS
Neutral
Advanced Accelerator downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jessica Fye downgraded Advanced Accelerator Applications (AAAP) to Neutral citing the proposed Novartis (NVS) tender offer. The analyst says the stock is already reflecting a very high likelihood of the deal closing. She raised her price target for the shares to $82 from $53.
12/01/17
SBSH
12/01/17
DOWNGRADE
Target $380
SBSH
Neutral
Regeneron downgraded to Neutral from Buy at Citi
Citi analyst Robyn Karnauskas downgraded Regeneron Pharmaceuticals (REGN) to Neutral and cut her price target for the shares to $380 from $480. The biotechnology company closed yesterday up 1% to $361.86. The analyst believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. It is hard to believe that RTH258 would not have a price impact, at minimum, on Regeneron's Eylea, Karnauskas tells investors in a research note. The analyst points out that her dermatologist survey came back bullish for Regeneron's Dupixent. While she expects the drug to beat expectations for 2018, the analyst feels this won't be enough to offset the overhang on shares from Eylea competition.

TODAY'S FREE FLY STORIES

VMC

Vulcan Materials

$122.21

-0.715 (-0.58%)

11:07
12/12/17
12/12
11:07
12/12/17
11:07
Conference/Events
Vulcan Materials management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.64

0.62 (4.13%)

11:05
12/12/17
12/12
11:05
12/12/17
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGU

Agrium

$110.72

2.71 (2.51%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Hot Stocks
Agrium to acquire Louis Dreyfus Company's Macrofertil fertilizer business »

Agrium announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Upgrade
Spark Therapeutics rating change  »

Follow-up: Spark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GRPN

Groupon

$5.86

0.05 (0.86%)

10:57
12/12/17
12/12
10:57
12/12/17
10:57
Recommendations
Groupon analyst commentary  »

Groupon selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$51.62

0.19 (0.37%)

10:55
12/12/17
12/12
10:55
12/12/17
10:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

10:55
12/12/17
12/12
10:55
12/12/17
10:55
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

10:54
12/12/17
12/12
10:54
12/12/17
10:54
Upgrade
Spark Therapeutics rating change  »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GSK

GlaxoSmithKline

$35.53

0.22 (0.62%)

10:53
12/12/17
12/12
10:53
12/12/17
10:53
Hot Stocks
FDA approves expanded use of GlaxoSmithKline's Nucala »

The FDA expanded the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TRIP

TripAdvisor

$35.32

0.82 (2.38%)

10:48
12/12/17
12/12
10:48
12/12/17
10:48
Hot Stocks
TripAdvisor, ReviewPush form licensing partnership for restaurant reviews »

ReviewPush announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$55.00

9.925 (22.02%)

, MS

Morgan Stanley

$53.09

0.32 (0.61%)

10:46
12/12/17
12/12
10:46
12/12/17
10:46
Hot Stocks
Overstock rises after Morgan Stanley discloses stake ahead of crypto launch »

Shares of Overstock…

OSTK

Overstock.com

$55.00

9.925 (22.02%)

MS

Morgan Stanley

$53.09

0.32 (0.61%)

BTC

Bitcoin

BITCOIN

Bitcoin

QVCA

QVC Group

$24.52

-0.27 (-1.09%)

TJX

TJX

$73.55

0.25 (0.34%)

COST

Costco

$188.86

0.79 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

, EA

Electronic Arts

$107.92

2.65 (2.52%)

10:44
12/12/17
12/12
10:44
12/12/17
10:44
Hot Stocks
Goldman ups Activision Blizzard, cuts EA in video game ratings shuffle »

Ahead of 2018, Goldman…

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

EA

Electronic Arts

$107.92

2.65 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

TMUS

T-Mobile

$63.07

0.53 (0.85%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Conference/Events
T-Mobile to host business news update conference call »

T-Mobile's President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MMM

3M

$236.76

-2.54 (-1.06%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Recommendations
3M analyst commentary  »

3M guidance solid versus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SQ

Square

$39.23

0.9318 (2.43%)

10:40
12/12/17
12/12
10:40
12/12/17
10:40
Options
Sizable put buyer in Square as shares rally »

Sizable put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

WWE

WWE

$30.94

0.24 (0.78%)

10:37
12/12/17
12/12
10:37
12/12/17
10:37
Conference/Events
WWE management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VKTX

Viking Therapeutics

$3.97

-0.11 (-2.70%)

10:35
12/12/17
12/12
10:35
12/12/17
10:35
Conference/Events
Viking Therapeutics management to meet with Maxim »

Meetingsto be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

  • 28

    Dec

TSLA

Tesla

$328.91

13.78 (4.37%)

, PEP

PepsiCo

$117.97

0.58 (0.49%)

10:34
12/12/17
12/12
10:34
12/12/17
10:34
Hot Stocks
Tesla jumps as PepsiCo makes biggest public pre-order of Semi trucks »

Shares of Tesla (TSLA)…

TSLA

Tesla

$328.91

13.78 (4.37%)

PEP

PepsiCo

$117.97

0.58 (0.49%)

WMT

Walmart

$97.02

0.09 (0.09%)

DPSGY

Deutsche Post

$47.34

-0.26 (-0.55%)

JBHT

J.B. Hunt

$111.30

-1.21 (-1.08%)

BUD

AB InBev

$111.30

-0.12 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Jan

  • 20

    Feb

NICE

Nice

$87.68

-0.15 (-0.17%)

10:32
12/12/17
12/12
10:32
12/12/17
10:32
Conference/Events
Nice management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 26

    Feb

EA

Electronic Arts

$107.92

2.65 (2.52%)

10:30
12/12/17
12/12
10:30
12/12/17
10:30
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

10:30
12/12/17
12/12
10:30
12/12/17
10:30
General news
Euro$ interest rate futures are lower »

Euro$ interest rate…

IPGP

IPG Photonics

$206.65

1.39 (0.68%)

10:29
12/12/17
12/12
10:29
12/12/17
10:29
Conference/Events
IPG Photonics management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

EVI

EnviroStar

$31.45

0.85 (2.78%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Hot Stocks
EnviroStar declares 12c per share special cash dividend »

EnviroStar announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KMT

Kennametal

$45.81

-0.15 (-0.33%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Conference/Events
Kennametal to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RPD

Rapid7

$18.77

0.03 (0.16%)

10:24
12/12/17
12/12
10:24
12/12/17
10:24
Conference/Events
Rapid7 to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.